Hsp90 is an ATP-dependent molecular chaperone that assists folding and conformational maturation/maintenance of many proteins. It is a potential cancer drug target because it chaperones oncoproteins. A prokaryotic homolog of Hsp90 (HtpG) is essential for thermo-tolerance in some bacteria and virulence of zoonotic pathogens. To identify a new class of small molecules which target prokaryotic and eukaryotic Hsp90s, we studied the effects of a naturally occurring cyclic sesquiterpene, zerumbone, which inhibits proliferation of a wide variety of tumor cells, on the activity of Hsp90. Zerumbone enhanced the ATPase activity of cyanobacterial Hsp90 (Hsp90SE), yeast Hsp90, and human Hsp90α. It also enhanced the catalytic efficiency of Hsp90SE by greatly increasing kcat. Mass analysis showed that zerumbone binds to cysteine side chains of Hsp90SE covalently. Mutational studies identified 3 cysteine residues (one per each domain of Hsp90SE) that are involved in the enhancement, suggesting the presence of allosteric sites in the middle and C-terminal domains of Hsp90SE. Treatment of cyanobacterial cells with zerumbone caused them to become very temperature-sensitive, a phenotype reminiscent of cyanobacterial Hsp90 mutants, and also decreased the cellular level of linker polypeptides that are clients for Hsp90SE. Zerumbone showed cellular toxicity on cancer-derived mammalian cells by inducing apoptosis. In addition, zerumbone inhibited the binding of Hsp90/Cdc37 to client kinases. Altogether, we conclude that modification of cysteine residues of Hsp90 by zerumbone enhances its ATPase activity and inhibits physiological Hsp90 function. The activation of Hsp90 may provide new strategies to inhibit its chaperone function in cells.
-
Cover Image
Cover Image
Cartoon illustration of the simultaneous binding of PAP (a competitive inhibitor of the physiological enzyme co-factor adeonosine 3′-phosphate 5′-phosphosulfate, PAPS) and a heptapeptide saccharide substrate (sticks), poised for sulfation (dashed line) in the active site of heparan sulfate 2-O-sulfotransferase (PDB ID: 4NDZ). The PAP(S)-binding site and the oligosaccharide-binding sites provide dual opportunities for the screening, identification and rational design of small molecule inhibitors of this enzyme, which include the highly sulfated polyanionic drug suramin and the promiscuous protein kinase inhibitor rottlerin. Rottlerin competes with the PAPS co-factor in sulfotransferases, opening the door for the discovery and optimisation of other kinase inhibitors that inhibit these classes of enzyme, including protein tyrosine sulfotransferases (TPSTs). For further details, see the article by Byrne et al. in this issue (pages 2417–2433) and its companion article on pages 2435–2455. Image kindly provided by Neil Berry and Patrick Eyers.
Stimulation of the ATPase activity of Hsp90 by zerumbone modification of its cysteine residues destabilizes its clients and causes cytotoxicity
Hitoshi Nakamoto, Yosuke Amaya, Taiwa Komatsu, Takehiro Suzuki, Naoshi Dohmae, Yusuke Nakamura, Ibrahim Jantan, Yoshihiko Miyata; Stimulation of the ATPase activity of Hsp90 by zerumbone modification of its cysteine residues destabilizes its clients and causes cytotoxicity. Biochem J 16 August 2018; 475 (15): 2559–2576. doi: https://doi.org/10.1042/BCJ20180230
Download citation file:
Sign in
Sign in to your personal account
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Cited By
Follow us on Twitter @Biochem_Journal
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() View past webinars > |